Bibliografía del artículo
1. Pungalia RS, D'Amico AV, Catalona WJ, Roehl KA, Kuntz KM. Impact of age, benign prostatic hyperplasia and cáncer on prostate specific antigen level. Cancer 106:1507-13, 2006.
2. Boseman CB, Carver BS, Eastham JA, Veneble DD. Treatment of chronic prostatitis lowers serum prostate specific antigen. J Urol 167:1723-6, 2002.
3. Jemel A, Siegel R, Ward E, Murray T, Xu J, Smigal C et al. Cancer statistics. Cancer J Clin 56:106-30, 2006.
4. Krumholtz JS, Carvalhal GF, Tamos CG, et al. Prostate specific antigen cutoff of 2.6 ng/ml for prostate cáncer screening is associated with favourable pathologic tumor features. Urology 60:469-473, 2002.
5. Auprich M, Augustin H, Budaus L et al. A comparative performance analysis of total APE, percentage free APE, APE velocity and urinary PCA3 in the first, second and third repeat prostate biopsy. BJU Int 109:1627-35, 2011.
6. Ross PL, Scardino PT, Kattan MW. A catalog of prostate cancer nomograms. J Urol 165:1562-1568, 2001.
7. Vickers AJ, Savage C, O'Brien MF, et al. Systemic review of pretreatment APE velocity and doubling time as predictors for prostate cancer. J Clin Oncol 27:398-403, 2009.
8. Schroder FH, Roobol MJ, Van der Kwast T, et al. Does APE velocity predict prostate cancer in pre-screened populations? Eur Urol 49:460-465, 2006.
9. Schroeder FH, Hugosson J, Roobel MJ, Tammela TLJ, Ciatto S, Nelen V et al. Screening and prostate cáncer mortality in a randomized European study. N Eng J Med 360:1320-1328, 2009.
10. Andiole GL, Grubb RL III, Buys SS, Chia D, Church TR, Fouad MN et al. Mortality results from a randomized prostate cancer screening trial. NEJM 360:1310-19, 2009.
11. Postma R, Roobol M, Schroeder FH, van der Kwast TH. Lesions predictive for prostate cáncer in a screened population: first and second screening round findings. Prostate 61:260-6, 2004.
12. Mian BM, Naya Y, Okihara K, Vakar-Lopez F, Troncosos P, Babaian RJ. Predictors of cancer in repeat extended multisite prostate biopsy in men with previous extended multisite biopsy. Urology 60:836-40, 2002.
13. Antunes AA, Freire GC, Aiello Filho D, Cury J, Srougi M. Analysis of the risk factors for incidental carcinoma of the prostate in patients with benign prostatic hyperplasia. Clinics 61:545-550, 2006.
14. Mulholland SG, et al. Detection of hematogenous micrometastasis in patients with prostate cancer. Cancer Res 52:6110-6112, 1992.
15. Zhou M, Chinnaiyan AM, Lleer CG et al. Alpha-methylacyl-CoA racemase: a novel tumor marker over-expressed in several human cancers and their precursor lesions. Am J Surg Pathol 26:926-31, 2002.
16. Beach R, Gown AM, Peralta-Venturina MN et al. P504S immunohistochemical detection in 405 prostatic specimens including 376 18-guage needle biopsies. Am J Surg Pathol 26:1588-96, 2002.
17. Murray NP, Reyes E, Badinez L et al. Circulating prostate cells found in men with benign disease are P504S negative: Clinical Implications. J Oncol ID 165014 e-pub http.//dx.doi.org/10.1155/2013/165014.
18. Murray NP, Reyes E, Tapia P, Orellana N, Dueñas R, Fuentealba C, Badinez L. Diagnostic Performance of malignant prostatic cells detected in blood for early detection of prostate cancer: comparison to prostatic biopsy. Arch Esp Urol 64:961-971, 2011.
19. Stott SL, Lee RJ, Nagrath S, Yu M, Miyamoto DT, Ulkus L, et al. Isolation and characterization of circulating tumor cell from patients with localized and metastatic prostate cancer. Sci Transl Med 25:25, 2010.
20. Fizazi K, Morat L, Chauveinc L, Prapotnich D, De Crevoisier R, Escudier B et al High detection rate of circulating tumor cells in blood of patients with prostate cancer using telomerase activity. Ann Oncol 18:518-21, 2007.
21. Moll R, Divo M, Langbein L. The human keratins: biology and pathology. Histochemistry and Cell Biology 129:705-733, 2008.
22. Helo P, Cronin AM, Danila DC, Wenske S, Gonzalez-Espinoza R, Anand A, et al. Circulating prostate tumor cells detected by RT-PCR in men with localized or castrate refractory prostate cancer: concordance with CellSearch assay and association with bone metastasis and with survival. Clin Chem 55:765-773, 2009.
23. Schaffer DR, Leversha MA, Danila DC. Circulating tumor cell analysis in patients with progressive castration resistant prostate cancer. Clin Cancer Res 13:2023-2029, 2007.
24. Went PT, Lugli A, Meier S et al. Frequent EpCam protein expression in human carcinomas. Hum Pathol 1:122-128, 2004.
25. Paterlini-Brechot P, Benali NL. Circulating tumor cells detection: clinical impact and future directions. Cancer Letters 2:180-204, 2007.
26. Raimondi C, Gradilone A. Naso G, Vincenzi B, Petracca A, Nicolazzo C et al. Epithelial-mesenchymal transition and stemness features in circulating tumor cells from breast cancer patients. Breast Cancer Res Treat (Epub ahead of print), 2011.
27. Mikolajczyk SD, Millar LS, Tsinberg P, Coutts SM, Zomorrodi M, Pham T, et al. Detection of EpCAM negative and cytokeratin negative circulating tumor cells in peripheral blood. J Oncol (epub 2011 252361 Apr 19), 2011.
28. Rietbergen JB, Kruger AE, Krause R, Schroder F. Complications of transrectal ultrasound guided systematic sextant biopsies of prostate: evaluation of complication rates and risk factors within a population based screening population. Urol 49:875-880, 1997.